Skip to main content
Journal cover image

Inhibition of the transcriptional activator protein nuclear factor kappaB prevents hemodynamic instability associated with the whole-body inflammatory response syndrome.

Publication ,  Other
Kovacich, JC; Boyle, EM; Morgan, EN; Canty, TG; Farr, AL; Caps, MT; Frank, N; Pohlman, TH; Verrier, ED
Published in: J Thorac Cardiovasc Surg
July 1999

BACKGROUND: The transcription factor nuclear factor kappaB mediates the expression of a number of inflammatory genes involved in the whole-body inflammatory response to injury. We and others have found that dithiocarbamates specifically inhibit nuclear factor kappaB-mediated transcriptional activation in vitro. OBJECTIVE: We hypothesized that inhibition of nuclear factor kappaB with dithiocarbamate treatment in vivo would attenuate interleukin 1 alpha-mediated hypotension in a rabbit model of systemic inflammation. METHODS: New Zealand White rabbits were anesthetized and cannulated for continuous hemodynamic monitoring during 240 minutes. Rabbits were treated intravenously with either phosphate-buffered saline solution or 15 mg/kg of a dithiocarbamate, either pyrrolidine dithiocarbamate or proline dithiocarbamate, 60 minutes before the intravenous infusion of 5 micrograms/kg interleukin 1 alpha. Nuclear factor kappaB activation was evaluated by electrophoretic gel mobility shift assay of whole-tissue homogenates. RESULTS: Infusion of interleukin 1 alpha resulted in significant decreases in mean arterial pressure and systemic vascular resistance, both of which were prevented by treatment with dithiocarbamate. Pyrrolidine dithiocarbamate induced a significant metabolic acidosis, whereas proline dithiocarbamate did not. Nuclear factor kappaB-binding activity was increased within heart, lung, and liver tissue 4 hours after interleukin 1 alpha infusion. Treatment with dithiocarbamate resulted in decreased nuclear factor kappaB activation in lung and liver tissue with respect to that in control animals. CONCLUSIONS: These results demonstrate that nuclear factor kappaB is systemically activated during whole-body inflammation and that inhibition of nuclear factor kappaB in vivo attenuates interleukin 1 alpha-induced hypotension. Nuclear factor kappaB thus represents a potential therapeutic target in the treatment of hemodynamic instability associated with the whole-body inflammatory response.

Duke Scholars

Published In

J Thorac Cardiovasc Surg

DOI

ISSN

0022-5223

Publication Date

July 1999

Volume

118

Issue

1

Start / End Page

154 / 162

Location

United States

Related Subject Headings

  • Thiocarbamates
  • Systemic Inflammatory Response Syndrome
  • Respiratory System
  • Random Allocation
  • Rabbits
  • Pyrrolidines
  • Proline
  • NF-kappa B
  • Interleukin-1
  • Infusions, Intravenous
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kovacich, J. C., Boyle, E. M., Morgan, E. N., Canty, T. G., Farr, A. L., Caps, M. T., … Verrier, E. D. (1999). Inhibition of the transcriptional activator protein nuclear factor kappaB prevents hemodynamic instability associated with the whole-body inflammatory response syndrome. J Thorac Cardiovasc Surg. United States. https://doi.org/10.1016/s0022-5223(99)70154-6
Kovacich, J. C., E. M. Boyle, E. N. Morgan, T. G. Canty, A. L. Farr, M. T. Caps, N. Frank, T. H. Pohlman, and E. D. Verrier. “Inhibition of the transcriptional activator protein nuclear factor kappaB prevents hemodynamic instability associated with the whole-body inflammatory response syndrome.J Thorac Cardiovasc Surg, July 1999. https://doi.org/10.1016/s0022-5223(99)70154-6.
Kovacich JC, Boyle EM, Morgan EN, Canty TG, Farr AL, Caps MT, et al. Inhibition of the transcriptional activator protein nuclear factor kappaB prevents hemodynamic instability associated with the whole-body inflammatory response syndrome. Vol. 118, J Thorac Cardiovasc Surg. 1999. p. 154–62.
Kovacich, J. C., et al. “Inhibition of the transcriptional activator protein nuclear factor kappaB prevents hemodynamic instability associated with the whole-body inflammatory response syndrome.J Thorac Cardiovasc Surg, vol. 118, no. 1, July 1999, pp. 154–62. Pubmed, doi:10.1016/s0022-5223(99)70154-6.
Kovacich JC, Boyle EM, Morgan EN, Canty TG, Farr AL, Caps MT, Frank N, Pohlman TH, Verrier ED. Inhibition of the transcriptional activator protein nuclear factor kappaB prevents hemodynamic instability associated with the whole-body inflammatory response syndrome. J Thorac Cardiovasc Surg. 1999. p. 154–162.
Journal cover image

Published In

J Thorac Cardiovasc Surg

DOI

ISSN

0022-5223

Publication Date

July 1999

Volume

118

Issue

1

Start / End Page

154 / 162

Location

United States

Related Subject Headings

  • Thiocarbamates
  • Systemic Inflammatory Response Syndrome
  • Respiratory System
  • Random Allocation
  • Rabbits
  • Pyrrolidines
  • Proline
  • NF-kappa B
  • Interleukin-1
  • Infusions, Intravenous